| Title : A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon) - Forette_1999_Eur.J.Neurol_6_423 |
| Author(s) : Forette F , Anand R , Gharabawi G |
| Ref : Eur Journal of Neurology , 6 :423 , 1999 |
| Abstract : Forette_1999_Eur.J.Neurol_6_423 |
| ESTHER : Forette_1999_Eur.J.Neurol_6_423 |
| PubMedSearch : Forette_1999_Eur.J.Neurol_6_423 |
| PubMedID: 10362894 |
Forette F, Anand R, Gharabawi G (1999)
A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon)
Eur Journal of Neurology
6 :423
Forette F, Anand R, Gharabawi G (1999)
Eur Journal of Neurology
6 :423